CA3091373A1 - Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint - Google Patents

Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint Download PDF

Info

Publication number
CA3091373A1
CA3091373A1 CA3091373A CA3091373A CA3091373A1 CA 3091373 A1 CA3091373 A1 CA 3091373A1 CA 3091373 A CA3091373 A CA 3091373A CA 3091373 A CA3091373 A CA 3091373A CA 3091373 A1 CA3091373 A1 CA 3091373A1
Authority
CA
Canada
Prior art keywords
cancer
antibody
modulator
subject
immune checkpoint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3091373A
Other languages
English (en)
French (fr)
Inventor
Sanjeev REDKA
Mammatha REDDY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apollomics Inc USA
Original Assignee
Apollomics Inc USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apollomics Inc USA filed Critical Apollomics Inc USA
Publication of CA3091373A1 publication Critical patent/CA3091373A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3091373A 2018-02-17 2019-02-17 Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint Pending CA3091373A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862631771P 2018-02-17 2018-02-17
US62/631,771 2018-02-17
US201862757729P 2018-11-08 2018-11-08
US62/757,729 2018-11-08
PCT/US2019/018377 WO2019161320A1 (en) 2018-02-17 2019-02-17 Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint

Publications (1)

Publication Number Publication Date
CA3091373A1 true CA3091373A1 (en) 2019-08-22

Family

ID=67620025

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3091373A Pending CA3091373A1 (en) 2018-02-17 2019-02-17 Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint

Country Status (6)

Country Link
US (1) US20200405719A1 (https=)
EP (1) EP3752528A4 (https=)
JP (2) JP2021515032A (https=)
CN (1) CN112424222A (https=)
CA (1) CA3091373A1 (https=)
WO (1) WO2019161320A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3091373A1 (en) * 2018-02-17 2019-08-22 Apollomics Inc. Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint
JP2023523295A (ja) * 2020-04-26 2023-06-02 アポロミクス インコーポレイテッド Ｃ－ｍｅｔ阻害剤のための新規医薬製剤
EP4159238A4 (en) * 2020-06-02 2024-08-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. COMBINED PHARMACEUTICAL COMPOSITION OF C-MET KINASE INHIBITOR AND ANTI-PD-L1 ANTIBODY
CN113105436B (zh) * 2021-04-20 2022-07-01 西格莱(苏州)生物医药有限公司 吡唑类化合物的制备方法及其中间体
WO2023172629A2 (en) * 2022-03-08 2023-09-14 Brown University Anticancer maleimide derivatives for use with immune checkpoint blockade
WO2025129332A1 (en) * 2023-12-21 2025-06-26 11949098 Canada Inc. (Nuredco) C/O Jean I. Tchervenkov Method of prognosis and monitoring of cancer patient and of determining immunological status of a subject

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101050829B1 (ko) * 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
EP3122900A1 (en) * 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
KR102524920B1 (ko) * 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 항-pd-1 항체
US10435470B2 (en) * 2014-08-05 2019-10-08 Cb Therapeutics, Inc. Anti-PD-L1 antibodies
AU2015327868A1 (en) * 2014-10-03 2017-04-20 Novartis Ag Combination therapies
TWI695837B (zh) * 2014-12-04 2020-06-11 比利時商健生藥品公司 作為激酶調節劑之三唑並嗒
RS61152B2 (sr) * 2015-05-12 2024-06-28 Hoffmann La Roche Terapeutski i dijagnostički postupci za lečenje raka
CA3000386A1 (en) * 2015-09-30 2017-04-06 Merck Patent Gmbh Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
HK1254635A1 (zh) * 2015-12-17 2019-07-26 Novartis Ag C-met抑制剂与pd-1抗体分子的组合及其用途
CA3091373A1 (en) * 2018-02-17 2019-08-22 Apollomics Inc. Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint
EP4159238A4 (en) * 2020-06-02 2024-08-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. COMBINED PHARMACEUTICAL COMPOSITION OF C-MET KINASE INHIBITOR AND ANTI-PD-L1 ANTIBODY

Also Published As

Publication number Publication date
JP2021515032A (ja) 2021-06-17
US20200405719A1 (en) 2020-12-31
EP3752528A1 (en) 2020-12-23
WO2019161320A1 (en) 2019-08-22
CN112424222A (zh) 2021-02-26
EP3752528A4 (en) 2021-11-03
JP2024009886A (ja) 2024-01-23

Similar Documents

Publication Publication Date Title
US12083112B2 (en) Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
US20200405719A1 (en) Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint
US11891450B2 (en) Anti-CD47 agent-based treatment of CD20-positive cancer
US20190270812A1 (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
JP7482180B2 (ja) 癌のための併用療法
EP3728313B1 (en) Combination anti cancer therapy with an iap antagonist and an anti pd-1 molecule
MD3932951T2 (ro) Metode de tratament al cancerului de piele prin administrarea inhibitorului PD-1
JP2019515916A (ja) グロボシリーズの抗原を介した免疫活性化又は免疫調節によるがん免疫療法
JP2022082565A (ja) がんを処置するための方法
Dickinson et al. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma
CN109153722A (zh) 用于治疗癌症的方法
US20220160718A1 (en) Compositions and methods of treating cancer
US20220025036A1 (en) Use of il-1beta binding antibodies
Erciyestepe et al. Distribution of side effects of anti-EGFR treatments in patients with metastatic colorectal cancer and evaluation of their relationship with survival
Rajhans et al. Single-Cell ATAC and Single-Nucleus RNA Sequencing Uncovers Cellular Heterogeneity Within Pancreatic Neuroendocrine Tumors
KR20260008112A (ko) 파르네실트랜스퍼라제 억제제 및 pi3k 억제제를 사용한 편평 세포 암종의 치료 방법
WO2016113572A1 (en) Insulin-like growth factor inhibitor and chemotherapeutic agent for use in cancer therapy
HK1232153B (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240216

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250904

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260331